EP300 and Alzheimer disease: Vorinostat may also have potential value as a treatment for AD through its effects on the CREB-binding protein (CBP)/E1A-binding protein p300 (EP300) signaling pathway (Rouaux, Loeffler & Boutillier, 2004).